- 1. Committee for Proper Use of Pediatric Drugs
- 2. Pharmaceuticals and Medical Devices Safety Information
- 3. Information on P-MCS DB Usage
- 4. Information on Publication
1. Committee for Proper Use of Pediatric Drugs
- Report on 1st Committee in FY 2022
- Report on 2nd Committee in FY 2021
- Report on 1st Committee in FY 2021
- Report on 2nd Committee in FY 2020
- Report on 1st Committee in FY 2020
- Report on 1st Committee in FY 2019
- Report on 2nd Committee in FY 2018
- Report on 1st Committee in FY 2018
- Report on Committee in FY 2017
2. Pharmaceuticals and Medical Devices Safety Information
3. Information on P-MCS DB Usage
- Summary on 4th Committee in 2024
- Summary on 3rd Committee in 2024
- Summary on 2nd Committee in 2024
- Summary on 1st Committee in 2024
- Summary on 9th Committee in 2023
- Summary on 8th Committee in 2023
- Summary on 7th Committee in 2023
- Summary on 6th Committee in 2023
- Summary on 5th Committee in 2023
- Summary on 4th Committee in 2023
- Summary on 3rd Committee in 2023
- Summary on 2nd Committee in 2023
- Summary on 1st Committee in 2023
- Summary on 8th Committee in 2022
- Summary on 7th Committee in 2022
- Summary on 6th Committee in 2022
- Summary on 5th Committee in 2022
- Summary on 4th Committee in 2022
- Summary on 3rd Committee in 2022
- Summary on 2nd Committee in 2022
- Summary on 1st Committee in 2022
- Summary on 3rd Committee in 2021
- Summary on 2nd Committee in 2021
- Summary on 1st Committee in 2021
4. Information on Publication
- Safety Signal Detection of Hepatocellular Injury following Methotrexate Administration in Children with Cancer and Rare Diseases
- Actual prescribing patterns of gastric acid secretion inhibitors in neonates using the Pediatric Medical Information Collection System database
- A Survey on Pediatric Drug-induced liver injury using the Pediatric Medical Information Collection System (P-MICS)
- Implementation status of therapeutic drug monitoring for antimicrobial agents in pediatrics: An analysis of data from the Pediatric Medical Information Collection System
- Investigation of the clinical status of pediatric patients with cGVHD in conjunction with a feasibility study of pediatric development of a therapeutic agent for chronic graft-versus-host disease (cGVHD)
- Research on the Clinical Practical Use of Pivoxil-Conjugated Antibodies and the Risk of Carnitine Deficiency Using Real-World Data
- Real-world Survey on Prescriptions for Propranolol in Patients with Pediatric and Congenital Heart Diseases
- Survey on Clinical Characteristics of Pediatric Drug-Induced Liver Injury using the Pediatric Medical Information Collection System
- Actual prescribing patterns of dexmedetomidine in neonates based on Pediatric Medical Information Collection System Database
- Feasibility Study on the Reality of TDM (Therapeutic Drug Monitoring) Clinical Use in Pediatrics by Using the Pediatric Medical Information Collection System
- Real world survey of prescription of propranolol for patients in pediatric and congenital heart diseases
- A study on Off-Label Use of Immunosuppressive Agents for Pediatric Nephrotic Syndrome Using Real-World Data
- A survey of pediatric hemophiliacs in the feasibility study of pediatric development of marstacimab
- Fact-finding survey on pediatric patients with C3 nephropathy and IC-MPGN
- Actual prescribing patterns of dexmedetomidine in neonates based on Pediatric Medical Information Collection System database
- Investigation of the number of children infected with COVID-19 in Japan accompanying the feasibility study of pediatric drug development
- An observational study using real-world data on the risk of adverse events of new quinolones in children
- A study on changes in the number of pediatric patients due to the state of emergency over COVID-19 using real-world data
The research and studies published on this website were conducted based on the analysis and evaluation of medical and related information provided by the medical institutions cooperating in the Pediatric Drug Information Collection Network Development Project for the purposes of establishing safety measures and developing pediatric drugs. Please allow us to express our deepest gratitude to the cooperating medical institutions and everyone involved in this project.